Healthcare
HLS Therapeutics Inc.(HLTRF)
Live Price
Offline$3.16
+0.00% today
1Y Change
-13.66%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $110.00M
- Revenue Growth
- -0.3%
- EPS Growth
- +35.5%
- Dividend Yield
- 0.0%
Coverage: 259 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
HLS Therapeutics Inc. (HLTRF) is a Healthcare stock with a market cap of $110.00M and listed on OTC. The stock last traded around $3.16 and down 13.7% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -0.3%, EPS growth of +35.5%, a dividend yield of 0.0%. What stands out right now is revenue -0.3%, EPS +35.5%, free cash flow +97.9% with operating margin -7.4% and ROIC -3.4%. Valuation is more restrained than many high-expectation growth names at price/sales 1.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines HLTRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.3% vs +7.6% peer median
Operating Margin
Below sector median
-7.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -0.3% and EPS is at +35.5%, with operating margin around -7.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +0.0% | +0.0% | -7.9% |
2026 Mar 12, 2026 | -33.3% | +0.0% | +0.0% | -10.8% |
2025 Nov 13, 2025 | -100.3% | -2.1% | -2.1% | -3.4% |
Benchmark Edge
HLTRF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HLTRF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HLTRF Max Drawdown
-25.37%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HLTRF and SPY.
Company Overview
HLS Therapeutics Inc.
Other OTC
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
- Leadership
- Craig Stuart Millian
- IPO Date
- Jan 27, 2010
- Employees
- 92
- Street Address
- 10 Carlson Court
- Mailing
- Etobicoke, ON, M9W 6L2
- Region
- Etobicoke, ON, CA
- Reporting Currency
- USD
- Investor Line
- +1 416 679 0599
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 8.3
- Price/Sales
- 1.9
- Price/Book
- 1.7
Growth
- Revenue
- -0.3%
- EPS
- +35.5%
- Free Cash Flow
- +97.9%
Profitability
- Gross Margin
- 71.9%
- Operating Margin
- -7.4%
- Net Margin
- -22.3%
- ROE
- -19.4%
- ROIC
- -3.4%
Balance Sheet
- Debt/Equity
- 0.81
- Current Ratio
- 1.11
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.